Abstract
The kidney plays an important role in the regulation of plasma glucose. It is estimated that greater than 99% of the renal glucose filtered by kidney glomerulus is resorbed by sodium-dependent glucose co-transporters (SGLTs), and that SGLT2 located in the proximal renal tubule achieves the most of this assignment. Studies of SGLT2 inhibitors indicate that raising renal glucose excretion by inhibiting SGLT2 helps effectively normalize the plasma glucose levels in individuals with type 2 diabetes mellitus (T2DM). This review discusses the discovery of SGLT2 inhibitors and the related structure-activity relationship (SAR) studies. The clinical trial data of dapagliflozin is also involved.
Keywords: Dapagliflozin, phlorizin, sodium-dependent glucose co-transporter, structure-activity relationships, type 2 diabetes mellitus, regulation of plasma glucose, SGLT2 inhibitors, relatedstructure-activity relationship, insulin deficiency
Current Topics in Medicinal Chemistry
Title: Development of Sodium-Dependent Glucose Co-Transporter 2 Inhibitors as Potential Anti-Diabetic Therapeutics
Volume: 11 Issue: 12
Author(s): Low-Tone Ho, Suvarn S. Kulkarni and Jinq-Chyi Lee
Affiliation:
Keywords: Dapagliflozin, phlorizin, sodium-dependent glucose co-transporter, structure-activity relationships, type 2 diabetes mellitus, regulation of plasma glucose, SGLT2 inhibitors, relatedstructure-activity relationship, insulin deficiency
Abstract: The kidney plays an important role in the regulation of plasma glucose. It is estimated that greater than 99% of the renal glucose filtered by kidney glomerulus is resorbed by sodium-dependent glucose co-transporters (SGLTs), and that SGLT2 located in the proximal renal tubule achieves the most of this assignment. Studies of SGLT2 inhibitors indicate that raising renal glucose excretion by inhibiting SGLT2 helps effectively normalize the plasma glucose levels in individuals with type 2 diabetes mellitus (T2DM). This review discusses the discovery of SGLT2 inhibitors and the related structure-activity relationship (SAR) studies. The clinical trial data of dapagliflozin is also involved.
Export Options
About this article
Cite this article as:
Ho Low-Tone, S. Kulkarni Suvarn and Lee Jinq-Chyi, Development of Sodium-Dependent Glucose Co-Transporter 2 Inhibitors as Potential Anti-Diabetic Therapeutics, Current Topics in Medicinal Chemistry 2011; 11 (12) . https://dx.doi.org/10.2174/156802611795860915
DOI https://dx.doi.org/10.2174/156802611795860915 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
Current Drug Targets Bronchopulmonary Dysplasia: An Imbalance of Inflammation
Current Respiratory Medicine Reviews Statins for the Prevention of First or Recurrent Stroke
Current Vascular Pharmacology Association Between C1236T (rs1128503) Variant in ABCB1 Gene and Breast Cancer Recurrence
Clinical Cancer Drugs Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design Diabetogenic Effects of Parthinium hysterophorous Induced Allergic Rhinitis
Inflammation & Allergy - Drug Targets (Discontinued) The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Induction and Amelioration of Environmental Stress in Isolated Islets Until Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions
Current Diabetes Reviews Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
Current Pharmaceutical Design Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients
Recent Patents on Anti-Cancer Drug Discovery Co-morbidity of Diabetes Mellitus and Orodental Diseases in Nigeria
Current Diabetes Reviews Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Natural Products as Farnesoid X Receptor (FXR) Agonists: Their Interactions with FXR Ligand Binding Region
Mini-Reviews in Organic Chemistry Antiplatelet for Coronary Artery Disease in Specific Condition “No Size Fits All”
Current Pharmaceutical Design Inhibitory Role of Resveratrol in the Development of Profibrogenesis and Fibrosis Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [ Diseases of the Kidney: Molecular Mechanisms and Current Therapy Executive Editor: Stephen I-Hong Hsu ]
Current Molecular Medicine